Jin Zhao

Jin Zhao


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
LWLinlin Wang
Linlin Wang
NSNing Shao
Ning Shao
YQYao yu Qu
Yao yu Qu
HSHuizhen Sun
Huizhen Sun
JZJin Zhao
Jin Zhao
Ovarian cancer is known for its high recurrence rates and poor prognosis, primarily due to chemoresistance, which significantly limits treatment options. Grasping the processes that contribute to chemoresistance is essential for the advancement of more efficient therapy methods. Firstly, we discovered that nuclear receptor subfamily 1 group D member 2 (NR1D2) was significantly elevated in cisplatin-resistant ovarian cancer cells, as revealed by RNA sequencing. Subsequent study indicated that NR1D2 was highly expressed in chemo-resistant ovarian cancer samples than the chemo-sensitive group, and negatively correlated with ovarian cancer patients’ survival. Moreover, NR1D2 silencing markedly contributed to cisplatin susceptibility of ovarian cancer cells. Additionally, the analysis of untargeted metabolomics mass spectrometry demonstrated a significant correlation between NR1D2 and the process of ferroptosis. Following this, we observed that NR1D2 silencing considerably increased the concentration of lipid peroxidation malondialdehyde (MDA) and ferrous ion, concomitant with downregulation of ferroptosis suppressor protein 1 (FSP1). Finally, the study revealed that NR1D2 influences immune infiltration in ovarian cancer. In summary, NR1D2 served as a prognostic biomarker in ovarian cancer and induced cisplatin-resistance. Furthermore, its expression was linked to ferroptosis and immune regulation within the tumor microenvironment. Targeting NR1D2 may provide a potential therapeutic strategy to enhance treatment efficacy in ovarian cancer.

1 January 2026 in Science Progress
Verified
Journal Article
Open access
WCWei Chen
Wei Chen
XCXiaoxi Chen
Xiaoxi Chen
LWLinlin Wang
Linlin Wang
YQYaoyu Qu
Yaoyu Qu
JZJin Zhao
Jin Zhao
HSHuizhen Sun
Huizhen Sun
Objective: Resistance to platinum-based chemotherapy remains a key obstacle in ovarian cancer treatment. This study aims to investigate the role of Uncoordinated 51-like kinase 2 (ULK2) in chemoresistance of ovarian cancer and elucidate its underlying mechanisms using 3D patient-derived organoids. Methods: Survival analysis was first performed using the Kaplan‒Meier plotter database. Immunohistochemical profiling delineated differential ULK2 expression patterns between chemoresistant and chemosensitive ovarian cancer tissue samples and organoids. ULK2 overexpression was achieved in cisplatin-resistant ovarian cancer organoids via lentiviral vector transduction. Then, we conducted an in-depth examination of the alterations in phosphorylated proteins induced by ULK2 overexpression using phosphoproteomics technology. To investigate the influence of ULK2 on chemosensitivity in ovarian cancer, Cell Counting Kit-8 (CCK-8) and in vivo experiments were conducted. Glycolysis was quantitatively assessed, and the underlying molecular mechanism was systematically investigated. Results: ULK2 high-expression ovarian cancer exhibited enhanced chemosensitivity and conferred survival advantage. CCK-8 and mouse experiments demonstrated that ULK2 overexpression decreased cisplatin resistance in patient-derived organoids. Gene Ontology (GO) analysis of phosphoproteomics profiling highlighted the predominant role of ULK2 in metabolic processes with experimental validation demonstrating its suppression of glycolysis. Mechanistically, ULK2 attenuated c-Jun expression by phosphorylation of c-Jun at Ser243. Moreover, c-Jun overexpression counteracted the chemosensitivity and glycolytic suppression induced by the ectopic ULK2 expression in ovarian cancer. Conclusions: ULK2 overcomes cisplatin resistance in ovarian cancer by downregulating glycolysis, a process mediated by phosphorylation-induced c-Jun degradation. These findings emphasized the role of ULK2 as a tumor suppressor, offering novel insights for chemotherapy in ovarian cancer.